1. Scrip
  2. >>R&D
  3. >>Clinical Trials

2017 Filing For Shionogi's Novel Flu Drug In Japan On Back Of Strong Phase III Data

 
• By Lucie Ellis-Taitt

Shionogi is on track to file its novel flu treatment S-033188 with regulators in Japan by the end of the year on the back of positive Phase III data.

Flu
2018 Japanese filing expected for Shionogi's novel flu treatment • Source: Shutterstock

Shionogi & Co. Ltd.'s novel influenza treatment S-033188 has met primary endpoints in a Japanese Phase III trial in healthy patients, setting the product up for potential approval in the country next year.

S-033188, a first-in-class antiviral, is being developed by Shionogi in Japan as a treatment for flu

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.